The active ingredient in Adronic is Zoledronic Acid, which belongs to a group of medicines called bisphosphonates. It is an inhibitor of osteoclast mediated bone resorption. The action of bisphosphonates on bone is based on their high affinity for mineralized bone. Intravenously administered Zoledronic Acid is rapidly distributed to bone. Zoledronic Acid is not metabolized and is excreted unchanged via the kidney.
Indications
● Treatment of osteoporosis in postmenopausal women to reduce the incidence of hip, vertebral and non-vertebral fractures
● Prevention of clinical fractures after a hip fracture
● Treatment of osteoporosis in men
● Treatment and prevention of glucocorticoid-induced osteoporosis
● Treatment of Paget’s disease of bone
FR
DE